What exactly did Nomura change on March 18, 2026?

Nomura downgraded Harrow Health, Inc. to **Neutral** on **March 18, 2026** and did not publish a new price target. This HROW analyst rating adjustment emphasized near-term execution concerns versus prior views.

How did the market react to the HROW analyst rating change?

The market reacted with a **-2.49%** drop, equal to **$-0.88** since the note. The HROW analyst rating shift likely softened immediate sentiment but did not erase divergent Buy signals from other firms.

Are there other analysts with a different view on Harrow Health, Inc.?

Yes. StreetInsider reported BTIG reiterated a **Buy** around the same time, creating a split in coverage. That contrast highlights the mixed HROW analyst rating landscape and the need to monitor subsequent notes.

What does Meyka AI say about HROW after the downgrade?

Meyka AI rates HROW with a grade of **B+** based on benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This HROW analyst rating context is one input among many and not investment advice.

Analyst Ratings

Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026

ByDanny Kontos March 19, 2026March 19, 2026

Nomura downgraded Harrow Health, Inc. (HROW) to Neutral on March 18, 2026, marking a clear shift in the street view. This HROW analyst rating move follows recent commentary and a modest share pullback of -2.49% or $-0.88 since the note. Nomura did not attach a public price target in its note, while StreetInsider also highlighted BTIG reiterating a Buy ahead of company presentations. Investors should weigh Nomura’s Neutral stance against BTIG’s Buy note and monitor upcoming events and earnings for trading signals and guidance.